Europe Alzheimer’s Disease Therapeutics and Diagnostics Industry Trends and Investment opportunities 2021
Market Segmentaion by Therapeutics (Marketed Drugs-(NMDA Receptor Antagonists, Cholinesterase Inhibitors), Pipeline Drugs), by Diagnostics (Computed tomography scan, Electroencephalography, Lumbar puncture test, Magnetic resonance imaging and Others)
(EMAILWIRE.COM, September 22, 2017 ) According to the report Europe Alzheimer’s Disease Therapeutics and Diagnostics Market, published by Market Data Forecast the Market was worth USD 2.58 billion in 2016 and estimated to be growing at a CAGR of 4.69%, to reach USD 3.24 billion by 2021. Alzheimer’s disease is a neurodegenerative, progressive, non-reversible ailment that is caused due to irregular functioning of brain cells i.e. breakdown of synaptic communication, ensuing in the loss of cerebral functions.
Certain signs and indications of Alzheimer’s disease are memory loss, sleeplessness, recurring movements, anxiety, despair and loss of reasoning capabilities. All memory and cerebral functioning may be lost in the advanced stages of the disease. According to the International Institute of Aging, Alzheimer’s disease is the most frequent form of dementia.
Browse market data tables and in-depth TOC of the Europe Alzheimer’s Disease Therapeutics and Diagnostics Industry to 2021 @ http://www.marketdataforecast.com/market-reports/europe-alzheimers-disease-therapeutics-and-diagnostics-market-2249/
The growth of the Europe Alzheimer’s disease Therapeutics and Diagnostics Market is mainly driven by factors such as rising geriatric populace, upsurge in healthcare spending and increasing government subsidy. In addition, growing healthcare cognizance and innovative diagnostic technologies are also stimulating the growth of the market. However, several factors such as stringent regulations, long authorization time for new medicines, and expiration of numerous patent drugs are restraining the growth of the Alzheimer’s disease Therapeutics and Diagnostics market in this region.
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/europe-alzheimers-disease-therapeutics-and-diagnostics-market-2249/request-sample
The Europe Alzheimer’s Disease Therapeutics and Diagnostics market is segmented based on Therapeutics and Diagnostics. The market for Alzheimer’s disease Therapeutics and Diagnostics, on the basis of Therapeutics is segmented into Marketed Drugs and Pipeline Drugs. Marketed Drugs are further segmented into NMDA Receptor Antagonists and Cholinesterase Inhibitors. Marketed Drugs lead the market on the basis of Therapeutics due to a large user base. On the basis of Diagnostics, the Alzheimer’s disease Therapeutics and Diagnostics market is segmented into Computed tomography scan, Electroencephalography, Lumbar puncture test, Magnetic resonance imaging, Positron emission tomography, and Others. Under this segment, Computed tomography scan segment leads the Alzheimer’s disease Therapeutics and Diagnostics market. Absence of alternative imaging tool for brain and neurological diagnostics is one of the crucial reasons for its large share.
The Europe market has been geographically segmented into Germany, U.K, France, Spain, and Italy. Populations in Europe are ageing, and with this will grow the frequency of Alzheimer’s disease. Roughly around 9 million people in the EU are projected to have dementia by 2030 – approaching twice the population of Denmark. Increasing R&D activity and a strong pipeline of disease modifying drugs are the crucial factors driving the growth of the market in this region.
Inquire before buying @ http://www.marketdataforecast.com/market-reports/europe-alzheimers-disease-therapeutics-and-diagnostics-market-2249/inquire
Leading companies have applied tactics such as mergers & acquisitions, collaborations, and joint ventures to gain a strong foothold in the market. The major companies dominating the Alzheimer’s Disease Therapeutics and Diagnostics market in this region are Abbvie Inc., Pfizer Inc., AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, H. Lundbeck A/S, Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc., Axon Neuroscience, Daiichi Sankyo Co, TauRx Therapeutics Ltd, Eli Lilly, F. Hoffmann La Roche AG, Johnson & Johnson, GE Healthcare, Janssen Pharmaceuticals etc.
About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
Certain signs and indications of Alzheimer’s disease are memory loss, sleeplessness, recurring movements, anxiety, despair and loss of reasoning capabilities. All memory and cerebral functioning may be lost in the advanced stages of the disease. According to the International Institute of Aging, Alzheimer’s disease is the most frequent form of dementia.
Browse market data tables and in-depth TOC of the Europe Alzheimer’s Disease Therapeutics and Diagnostics Industry to 2021 @ http://www.marketdataforecast.com/market-reports/europe-alzheimers-disease-therapeutics-and-diagnostics-market-2249/
The growth of the Europe Alzheimer’s disease Therapeutics and Diagnostics Market is mainly driven by factors such as rising geriatric populace, upsurge in healthcare spending and increasing government subsidy. In addition, growing healthcare cognizance and innovative diagnostic technologies are also stimulating the growth of the market. However, several factors such as stringent regulations, long authorization time for new medicines, and expiration of numerous patent drugs are restraining the growth of the Alzheimer’s disease Therapeutics and Diagnostics market in this region.
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/europe-alzheimers-disease-therapeutics-and-diagnostics-market-2249/request-sample
The Europe Alzheimer’s Disease Therapeutics and Diagnostics market is segmented based on Therapeutics and Diagnostics. The market for Alzheimer’s disease Therapeutics and Diagnostics, on the basis of Therapeutics is segmented into Marketed Drugs and Pipeline Drugs. Marketed Drugs are further segmented into NMDA Receptor Antagonists and Cholinesterase Inhibitors. Marketed Drugs lead the market on the basis of Therapeutics due to a large user base. On the basis of Diagnostics, the Alzheimer’s disease Therapeutics and Diagnostics market is segmented into Computed tomography scan, Electroencephalography, Lumbar puncture test, Magnetic resonance imaging, Positron emission tomography, and Others. Under this segment, Computed tomography scan segment leads the Alzheimer’s disease Therapeutics and Diagnostics market. Absence of alternative imaging tool for brain and neurological diagnostics is one of the crucial reasons for its large share.
The Europe market has been geographically segmented into Germany, U.K, France, Spain, and Italy. Populations in Europe are ageing, and with this will grow the frequency of Alzheimer’s disease. Roughly around 9 million people in the EU are projected to have dementia by 2030 – approaching twice the population of Denmark. Increasing R&D activity and a strong pipeline of disease modifying drugs are the crucial factors driving the growth of the market in this region.
Inquire before buying @ http://www.marketdataforecast.com/market-reports/europe-alzheimers-disease-therapeutics-and-diagnostics-market-2249/inquire
Leading companies have applied tactics such as mergers & acquisitions, collaborations, and joint ventures to gain a strong foothold in the market. The major companies dominating the Alzheimer’s Disease Therapeutics and Diagnostics market in this region are Abbvie Inc., Pfizer Inc., AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, H. Lundbeck A/S, Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc., Axon Neuroscience, Daiichi Sankyo Co, TauRx Therapeutics Ltd, Eli Lilly, F. Hoffmann La Roche AG, Johnson & Johnson, GE Healthcare, Janssen Pharmaceuticals etc.
About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
Contact Information:
Market Data Forecast.
Abhishek
Tel: +1-888- 702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Market Data Forecast.
Abhishek
Tel: +1-888- 702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results